CJC-1295 vs PT-141
CJC-1295 and PT-141 are both peptide compounds evaluated on Vial: CJC-1295 is available as a compounded preparation with clinical-trial evidence, and PT-141 is FDA approved with FDA-approval-level clinical evidence, offered by 16 and 9 verified providers respectively.
Vial summary · compiled from public records
At a glance
PT-141
Sold as Vyleesi
- Category
- Peptide
- FDA / legal status
- FDA Approved
- Route
- Subcutaneous
Side by side
| Field | CJC-1295 | PT-141 |
|---|---|---|
| Category | Peptide | Peptide |
| Brand names | — | Vyleesi |
| FDA / legal status | Compoundable | FDA Approved |
| Evidence tier | Clinical Trials | FDA Approved |
| Administration route | Subcutaneous | Subcutaneous |
| Compounding access | Available through 503A and 503B compounding pharmacies | FDA-approved product, dispensed by prescription |
| Providers on Vial | 16 listed | 9 listed |
| Typical price band | $$ to $$$ | $$ |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About CJC-1295
A synthetic analog of growth hormone-releasing hormone (GHRH), this 30-amino acid peptide is modified with a drug affinity complex (DAC) that extends its half-life by binding to serum albumin. It stimulates pulsatile growth hormone secretion from the anterior pituitary by activating GHRH receptors. The compound has been investigated in clinical research for growth hormone deficiency and conditions associated with impaired GH/IGF-1 axis function.
About PT-141
A synthetic cyclic heptapeptide melanocortin receptor agonist, bremelanotide (PT-141) acts primarily on MC4 receptors in the central nervous system to modulate sexual arousal pathways. The compound increases sexual desire through direct neurological mechanisms rather than peripheral vascular effects. Its primary clinical application is the treatment of hypoactive sexual desire disorder in premenopausal women.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.